News coverage about NxStage Medical (NASDAQ:NXTM) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. NxStage Medical earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news articles about the medical device company an impact score of 45.8894698723135 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Several research analysts have recently commented on the company. Zacks Investment Research lowered NxStage Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Canaccord Genuity restated a “hold” rating and set a $30.00 price target on shares of NxStage Medical in a research report on Tuesday, October 17th. Finally, Northland Securities restated a “hold” rating and set a $30.00 price target on shares of NxStage Medical in a research report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating and eight have issued a hold rating to the stock. The company has a consensus rating of “Hold” and an average target price of $30.25.
Shares of NxStage Medical (NASDAQ:NXTM) traded up $0.33 during midday trading on Tuesday, hitting $24.56. The stock had a trading volume of 575,350 shares, compared to its average volume of 478,000. The firm has a market capitalization of $1,604.81, a PE ratio of -350.86 and a beta of -0.08. NxStage Medical has a twelve month low of $20.45 and a twelve month high of $30.80.
In other NxStage Medical news, President Joseph E. Turk, Jr. sold 1,000 shares of the firm’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $27.56, for a total value of $27,560.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Winifred L. Swan sold 3,500 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $25.73, for a total value of $90,055.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,500 shares of company stock worth $302,590. Insiders own 4.70% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact NxStage Medical (NXTM) Stock Price” was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.truebluetribune.com/2018/01/03/nxstage-medical-nxtm-earning-somewhat-positive-news-coverage-analysis-shows.html.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.